Teachers Retirement System of The State of Kentucky Has $8.83 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Teachers Retirement System of The State of Kentucky trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,713 shares of the biopharmaceutical company's stock after selling 2,000 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Alnylam Pharmaceuticals were worth $8,833,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Whipplewood Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Finally, Washington Trust Advisors Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 61 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 1.5%

ALNY stock traded up $4.76 during trading on Tuesday, hitting $325.28. 1,268,974 shares of the company's stock traded hands, compared to its average volume of 853,616. The business has a fifty day simple moving average of $306.46 and a two-hundred day simple moving average of $272.05. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $333.70. The firm has a market capitalization of $42.41 billion, a P/E ratio of -155.64 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the previous year, the company earned ($0.16) EPS. The firm's revenue was up 20.2% compared to the same quarter last year. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ALNY. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an "overweight" rating in a report on Wednesday, July 16th. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a "buy" rating in a research report on Friday, July 11th. HC Wainwright restated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Stifel Nicolaus boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Finally, Jefferies Financial Group boosted their price objective on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research report on Monday, July 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $347.75.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.